Evidence map›Paper›PMID 36163427›Full record

ArticleBone marrow transplantation2022

Development and validation of a predictive model to guide the use of plerixafor in pediatric population.

Bernard Sebastien, Peter Cheverton, Catherine Magnin, Jihane Aouni, Remi Castan

Open access · hybridAbstract read
In one paragraph

Article in Bone marrow transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Bernard SebastienSanofi, Chilly-Mazarin, France. Bernard.Sebastien@sanofi.com.ORCID 0000-0002-4437-2880
Peter ChevertonCheverton Oncology Consultants Ltd, Bury St Edmunds, UK.
Catherine MagninSanofi, Gentilly, France.
Jihane AouniIvidata Group, Levallois-Perret, France.
Remi CastanSanofi, Chilly-Mazarin, France.
Sanofi (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plerixafor, a CXCR4 receptor antagonist, reduces the binding and chemotaxis of hematopoietic stem cells to the bone marrow stroma, resulting in predictable peak of cluster of differentiation 34

Indexed as

CyclamsHeterocyclic CompoundsMultiple MyelomaAntigens, CD34BenzylaminesChildGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHumansAntigens, CD34BenzylaminesCyclamsGranulocyte Colony-Stimulating FactorHeterocyclic Compounds

Identifiers

PMID36163427
PMCPMC9715428
OpenAlexW4297229306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.